Press Releases

NW Bio provides guidance on phase III trial enrollment timing: Completion expected to be faster or more efficient than relevant comparison trials Read More

Endpoint of Tumor Regression Could Be Seen Within Months BETHESDA, Md., March 5, 2013 — Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that its Phase I/II DCVax-Direct clinical trial for all inoperable solid tumor cancers is planned to begin within approximately the next sixty days. As a Phase I/II trial, this trial is not... Read More

Large International CRO With Extensive Experience Will Manage European Trial BETHESDA, Md., Feb. 15, 2013 — Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that, building upon nearly three years of  manufacturing development, regulatory processes and  clinical preparations in Europe, the Company has named a... Read More

CEO To Provide Update on Clinical Trials, Europe and Company Plans for 2013 BETHESDA, MD, Feb. 11, 2013 — Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Linda F. Powers, the Company’s Chairman and Chief Executive Officer, will be presenting at the 15th Annual BIO CEO and Investor Conference at 4:30 p.m. on... Read More

Dr. Bosch To Review DCVax® Portfolio Of Products For All Solid Tumor Cancers BETHESDA, Md., Jan. 29, 2013 — Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Dr. Marnix Bosch, the Company’s Chief Technical Officer, will be presenting at the Phacilitate Cell And Gene Therapy Forum 2013, today at 3:30 pm in a session... Read More